Hair loss treatment should target dermal white adipose tissue (DWAT) to restore hair follicles. Potential remedies include tocopherol (vitamin E), botox, rosiglitazone, niacin, kojyl cinnamate esters, and ADP355.
The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.
A 20-year-old started taking 1mg oral finasteride and 3mg oral minoxidil every other day for hair loss. They plan to focus on their hair and health over the summer and will update in November.
A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.
The user switched from finasteride to dutasteride for hair loss and saw significant improvement in under two months. They also microneedle, take supplements including collagen and vitamin D3, use ketoconazole shampoo, and noticed accidental hair regrowth with retinol application on their face.
A user is experiencing worsening hair loss despite using 2.5mg Dutasteride, RU58841, and Minoxidil daily for over 8 months. They are concerned that daily nicotine from vaping might be counteracting the treatments.
A user's successful hair regrowth journey using a cocktail of finasteride, minoxidil, and ketoconazole. The user started seeing noticeable results after 8 months and also incorporated saw palmetto, biotin, keratin, and dermarolling into their routine.
A female user in her mid-20s with androgenetic alopecia and suspected telogene effluvium who has been taking Dutasteride, Spironolactone, Minoxidil, Dermarolling, Ketoconazol shampoo, and Yaz contraception for her hair loss for the past 6 months. She had a small shed during this time that she believes to be stress related.
The user reported slight hair improvement using dietary changes, Nizoral shampoo, microneedling, and rosemary oil massages. They avoided medications like minoxidil and finasteride due to side effects concerns.
A user's progress with hair loss treatments, including minoxidil, microneedling, nizoral 2%, finasteride 0.5mg/day and 0.5mg/ml per day in minoxidil, as well as RU58841 purchased from Anagen Inc., which allowed the user to go outside without a hat or cap for two years.
A user is testing clascoterone (Winlevi) on their scalp for hair loss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.
The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.
The user shared their 18-month hair loss treatment progress, using finasteride three times a week, daily minoxidil, weekly vitamin D, and bi-weekly nizoral shampoo. They experienced initial shedding and greying, but are satisfied with the results.
A user shared their 11-week post-op hair transplant results, noting they use only vitamins, not minoxidil or finasteride. Replies suggest starting finasteride to maintain results, with mixed opinions on the current progress.
Sulforaphane shows potential for hair regrowth, with users reporting reduced shedding and regrowth. Some users combine it with Minoxidil and finasteride for better results.
RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.
Nutrafol helps improve hair thickness and hairline but may have potential health risks like liver damage and increased prostate cancer risk. The user plans to continue Nutrafol at a lower dosage while managing seborrheic dermatitis and considers future use of topical finasteride, minoxidil, rosemary oil, and microneedling.
The user "Dismal_Library_2264" shared their 11-month progress on a hair loss treatment regimen. They used dutasteride, topical minoxidil, dermarolling, a hair serum, and specific shampoos. They experienced some side effects but were overall satisfied with the results.
A 28-year-old underwent three hair transplants totaling 11,102 grafts at Eugenix, using finasteride and minoxidil to manage advanced hair loss. Despite limited density, the results are satisfactory, allowing the individual to feel presentable without a hat.
The user experienced regrowth and stabilization in hair density using finasteride, minoxidil, a derma roller, and an LLLT helmet, but noticed a recent decline in hair quality. They only take finasteride orally and are unsure about the effectiveness of the LLLT device.
An 18-year-old with Norwood 2 hair loss is considering finasteride treatment. Bloodwork shows testosterone and hormone levels mostly within normal ranges, except for low estradiol.
Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.
User reports almost 2 months on DUT and MIN for hair loss with positive results. Treatment includes 0.5mg dut (morning), 5mg oral min (night), and vitamin D and B12 supplements.
Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.
PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.
A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.
Several users shared their experiences with hair loss treatments, including Minoxidil, Finasteride, and microneedling, reporting varying degrees of hair regrowth. Despite some skepticism, users noted visible improvements over time, with some considering hair transplants as a future option.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
The user experienced severe hair shedding despite using oral finasteride, minoxidil, dutasteride, and RU58841, and was diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD). They are considering switching to topical treatments due to the ineffectiveness of their current regimen.